Core Viewpoint - Baxter International Inc. has declared a quarterly cash dividend of $0.29 per share, indicating a strong commitment to returning value to shareholders [1]. Group 1: Dividend Announcement - The quarterly cash dividend of $0.29 per share is payable on April 1, 2024, to stockholders of record as of March 1, 2024 [1]. - The indicated annual dividend rate is $1.16 per share of common stock [1]. Group 2: Company Overview - Baxter operates in the healthcare sector, providing a wide range of products including diagnostic, critical care, kidney care, nutrition, hospital, and surgical products [2]. - The company has been in operation for over 90 years, focusing on innovations that save and sustain lives [2]. - Baxter's products and digital health solutions are available in more than 100 countries, highlighting its global reach and commitment to advancing healthcare innovations [2].

Core Viewpoint - Baxter International Inc. reported better-than-expected adjusted earnings per share (EPS) for the fourth quarter of 2023, but the stock experienced a decline in pre-market trading despite the positive results [1][2]. Financial Performance - Adjusted EPS from continuing operations was 88 cents, exceeding the Zacks Consensus Estimate of 86 cents by 2.3% and improving 13% year-over-year [1]. - Total revenues from continued operations reached $3.89 billion, reflecting a 4% increase on a reported basis and 3% at constant currency, surpassing the Zacks Consensus Estimate by 2.4% [2]. - For the full year 2023, Baxter recorded total revenues of $14.81 billion, up 2% year-over-year, while adjusted EPS from continuing operations was $2.60, down 14% from the previous year [9]. Segment Performance - The Medical Products & Therapies segment generated sales of $1.32 billion, up 6% year-over-year [4]. - Infusion Therapies and Technologies sales totaled $1.04 billion, increasing by 5% year-over-year, while Advanced Surgery sales reached $278 million, up 7% [5]. - The Healthcare Systems and Technologies segment reported sales of $795 million, an 8% increase year-over-year [6]. - The Pharmaceuticals segment's sales were $596 million, up 8% year-over-year [6]. - The Kidney Care segment saw total sales of $1.16 billion, down 1% year-over-year, with Chronic Therapies sales at $950 million, down 2% [7]. Margin Analysis - Adjusted gross profit for the fourth quarter was $1.63 billion, a 5.7% increase year-over-year, with a gross margin improvement of 80 basis points to 42% [8]. - Adjusted operating income from continuing operations was $449 million, up 13% year-over-year, with an operating margin improvement of 90 basis points to 11.6% [8]. Future Guidance - For Q1 2024, Baxter anticipates sales growth of approximately 1% on a reported basis, with adjusted EPS expected between 59 cents and 62 cents [10]. - For the full year 2024, sales growth is projected to be nearly 2% on a reported basis, with adjusted EPS expected in the range of $2.85 to $2.95 [10].

FO URT H-Q UA RT ER 2023 EA RNI NGS Baxter International Inc. February 8, 2024 FORWA R D- LOOKING STAT EM ENT S This pr ...

Start Time: 08:30 January 1, 0000 9:32 AM ET Baxter International Inc. (NYSE:BAX) Q4 2023 Earnings Conference Call February 08, 2024, 08:30 AM ET Executives Clare Trachtman - VP, IR Jose Almeida - Chairman, President and CEO Joel Grade - EVP and CFO Analysts Travis Steed - Bank of America Securities Matt Miksic - Barclays Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Securities Matt Taylor - Jefferies Danielle Antalffy - UBS Operator Good morning, ladies and gentlemen, and welcome to Baxter Int ...

Baxter International (BAX) reported $3.89 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 0.1%. EPS of $0.88 for the same period compares to $0.88 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.8 billion, representing a surprise of +2.28%. The company delivered an EPS surprise of +2.33%, with the consensus EPS estimate being $0.86.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...

Baxter International (BAX) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.33%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.66 per share when it actually produced earnings of $0.68, delivering a surprise of 3.03%.Over the last fou ...

| --- | --- | |--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------| | UNITED STATES SECURITIES AND EXCHANGE Washington, D.C. 20549 | COMMISSION | | FORM 10-K | _____________________________________________________________________________________________ | (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com. The con ...

T HI RD-Q UA RT ER 2023 EA RNI NGS Baxter International Inc. November 2, 2023 FORWA R D- LOOKING STAT EM ENT S This pr ...

Baxter International Inc. (NYSE:BAX) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Joe Almeida - Chairman, Chief Executive Officer Joel Grade - Executive Vice President, Chief Financial Officer Brian Stevens - Senior Vice President, Chief Accounting Officer, Controller, former Interim CFO Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Conference Call Participants Matt Miksic - Barclays Vijay Kumar - Evercore ISI Rick Wise - Stifel Pito Chickerin ...